Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.

Argula RG, Kokosi M, Lo P, Kim HJ, Ravenel JG, Meyer C, Goldin J, Lee HS, Strange C, McCormack FX; MILES Study Investigators.

Ann Am Thorac Soc. 2016 Mar;13(3):342-9. doi: 10.1513/AnnalsATS.201509-631OC.

2.

Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.

Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J.

Am J Respir Crit Care Med. 2014 Dec 1;190(11):1273-82. doi: 10.1164/rccm.201405-0918OC.

3.

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.

Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group.

Lancet Respir Med. 2013 Aug;1(6):445-52.

4.

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group.

N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.

5.

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN.

N Engl J Med. 2008 Jan 10;358(2):140-51. doi: 10.1056/NEJMoa063564.

6.

COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.

Kato M, Kanehiro Y, Yoshimi K, Kodama Y, Sekiya M, Sato T, Takahashi K, Seyama K; Multicenter Lymphangioleiomyomatosis Sirolimus Trial for Safety Study Group.

Respir Investig. 2018 Nov;56(6):480-488. doi: 10.1016/j.resinv.2018.07.004. Epub 2018 Aug 22.

PMID:
30143460
7.

A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.

Lu C, Lee HS, Pappas GP, Dilling DF, Burger CD, Shifren A, Veeraraghavan S, Chapman JT, Parambil J, Ruoss SJ, Young LR, Hammes SR, Kopras EJ, Roads T, Krischer JP, McCormack FX; Trial of an Aromatase Inhibitor in Lymphangioleiomyomatosis Group.

Ann Am Thorac Soc. 2017 Jun;14(6):919-928. doi: 10.1513/AnnalsATS.201610-824OC.

PMID:
28570161
8.

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J.

Ann Intern Med. 2011 Jun 21;154(12):797-805, W-292-3. doi: 10.7326/0003-4819-154-12-201106210-00007.

9.

Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

Neurohr C, Hoffmann AL, Huppmann P, Herrera VA, Ihle F, Leuschner S, von Wulffen W, Meis T, Baezner C, Leuchte H, Baumgartner R, Zimmermann G, Behr J.

Respir Res. 2011 May 21;12:66. doi: 10.1186/1465-9921-12-66.

10.

Summaries for patients. Sirolimus therapy in patients with lymphangioleiomyomatosis.

[No authors listed]

Ann Intern Med. 2011 Jun 21;154(12):I44. doi: 10.7326/0003-4819-154-12-201106210-00003. No abstract available.

PMID:
21690578
11.

Sirolimus for lymphangioleiomyomatosis lesions.

Egan JJ, Remund KF, Corris P.

N Engl J Med. 2008 May 1;358(18):1963-4; author reply 1964. doi: 10.1056/NEJMc086040. No abstract available.

PMID:
18450609
12.

Durability of Sirolimus for Lymphangioleiomyomatosis.

Martirossian A, Shah S, Carrete L, Valle J, Valentine V.

Am J Med Sci. 2017 Dec;354(6):603-607. doi: 10.1016/j.amjms.2016.11.028. Epub 2016 Dec 5.

PMID:
29208258
13.

Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.

Crausman RS, Lynch DA, Mortenson RL, King TE Jr, Irvin CG, Hale VA, Newell JD Jr.

Chest. 1996 Jan;109(1):131-7.

PMID:
8549175
14.

Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.

Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K, Tanaka T, Yagi K, Young LR, McCormack FX, Nakata K.

Ann Am Thorac Soc. 2016 Nov;13(11):1912-1922.

PMID:
27513278
15.

Resolution of Thoracic and Abdominal Lymphangioleiomyomas in a Patient With Lymphangioleiomyomatosis Treated With Sirolimus.

Cabeza Osorio L, Ruiz Cobos MÁ, Casanova Espinosa Á.

Arch Bronconeumol. 2016 Jun;52(6):329-30. doi: 10.1016/j.arbres.2015.02.013. Epub 2015 Apr 23. English, Spanish. No abstract available.

16.

Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.

Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Takada T, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Arai T, Sugimoto C, Hattori N, Watanabe K, Tamada T, Akazawa K, Tanaka T, Nakata K.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1182-1189. doi: 10.1002/pds.4259. Epub 2017 Jul 28.

PMID:
28752672
17.

Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation.

Chen F, Omasa M, Kondo N, Fujinaga T, Shoji T, Sakai H, Bando T.

Ann Thorac Surg. 2009 Jan;87(1):e6-7. doi: 10.1016/j.athoracsur.2008.07.107.

PMID:
19101258
18.

Lymphangioleiomyomatosis.

Sclafani A, VanderLaan P.

N Engl J Med. 2018 Jun 7;378(23):2224. doi: 10.1056/NEJMicm1712581. No abstract available.

19.

SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.

Hecimovic A, Jakopovic M, Pavlisa G, Jankovic M, Vukic-Dugac A, Redzepi G, Brcic L, Samarzija M, Gupta N.

Lymphology. 2015 Jun;48(2):97-102.

PMID:
26714374
20.

Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangioleiomyomatosis.

Gupta N, Han MK, McCormack FX.

Ann Am Thorac Soc. 2015 Aug;12(8):1247-8. doi: 10.1513/AnnalsATS.201503-111LE. No abstract available.

Supplemental Content

Support Center